NO20060123L - Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi - Google Patents

Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Info

Publication number: NO20060123L
Authority: NO; Norway
Prior art keywords: cancer; disorder; steroid hormone; uterine; type
Prior art date: 2003-06-10

Application number

NO20060123A

Other languages

English (en)

Norwegian (no)

Inventor

Leena Hirvela

Nina Johansson

Pasi Koskimies

Olli Taneli Pentikainen

Tommi Nyronen

Tiina Annamaria Salminen

Mark Stuart Johnson

Pekka Lehtovuori

Original Assignee

Solvay Pharm Bv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-10

Filing date

2006-01-09

Publication date

2006-03-09

2006-01-09 Application filed by Solvay Pharm Bv filed Critical Solvay Pharm Bv

2006-03-09 Publication of NO20060123L publication Critical patent/NO20060123L/no

Links

UELJJSQADCDBMU-UHFFFAOYSA-N 3h-[1]benzothiolo[2,3-d]pyrimidin-4-one Chemical class S1C2=CC=CC=C2C2=C1N=CNC2=O UELJJSQADCDBMU-UHFFFAOYSA-N 0.000 title abstract 2
238000002560 therapeutic procedure Methods 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
230000001419 dependent effect Effects 0.000 abstract 3
201000010099 disease Diseases 0.000 abstract 3
208000035475 disorder Diseases 0.000 abstract 3
239000003270 steroid hormone Substances 0.000 abstract 3
208000002874 Acne Vulgaris Diseases 0.000 abstract 2
206010000496 acne Diseases 0.000 abstract 2
108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 abstract 1
208000005641 Adenomyosis Diseases 0.000 abstract 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 abstract 1
208000002177 Cataract Diseases 0.000 abstract 1
206010009944 Colon cancer Diseases 0.000 abstract 1
208000005171 Dysmenorrhea Diseases 0.000 abstract 1
206010013935 Dysmenorrhoea Diseases 0.000 abstract 1
206010058314 Dysplasia Diseases 0.000 abstract 1
206010014733 Endometrial cancer Diseases 0.000 abstract 1
206010014759 Endometrial neoplasm Diseases 0.000 abstract 1
201000009273 Endometriosis Diseases 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
208000001132 Osteoporosis Diseases 0.000 abstract 1
206010033128 Ovarian cancer Diseases 0.000 abstract 1
206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000004403 Prostatic Hyperplasia Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
206010039792 Seborrhoea Diseases 0.000 abstract 1
208000002495 Uterine Neoplasms Diseases 0.000 abstract 1
206010046798 Uterine leiomyoma Diseases 0.000 abstract 1
208000029742 colonic neoplasm Diseases 0.000 abstract 1
201000006828 endometrial hyperplasia Diseases 0.000 abstract 1
201000009274 endometriosis of uterus Diseases 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
201000010260 leiomyoma Diseases 0.000 abstract 1
208000007106 menorrhagia Diseases 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
210000002307 prostate Anatomy 0.000 abstract 1
201000007094 prostatitis Diseases 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
208000008742 seborrheic dermatitis Diseases 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
206010046766 uterine cancer Diseases 0.000 abstract 1
230000037303 wrinkles Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Neurology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Addiction (AREA)
Gynecology & Obstetrics (AREA)
Pregnancy & Childbirth (AREA)
Immunology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Plural Heterocyclic Compounds (AREA)
Joining Of Glass To Other Materials (AREA)

NO20060123A 2003-06-10 2006-01-09 Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi NO20060123L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47704703P	2003-06-10	2003-06-10
PCT/EP2004/006230 WO2005032527A2 (en)	2003-06-10	2004-06-09	Benzo (4, 5) thieno (2, 3-d) pyrimidin-4-ones and their use in therapy

Publications (1)

Publication Number	Publication Date
NO20060123L true NO20060123L (no)	2006-03-09

Family

ID=34421462

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060123A NO20060123L (no)	2003-06-10	2006-01-09	Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi

Country Status (24)

Country	Link
US (1)	US7465739B2 (pt)
EP (1)	EP1635839B1 (pt)
JP (1)	JP4605800B2 (pt)
KR (1)	KR20060054189A (pt)
CN (1)	CN1791412A (pt)
AR (1)	AR044650A1 (pt)
AT (1)	ATE479437T1 (pt)
AU (1)	AU2004277311B8 (pt)
BR (1)	BRPI0411295A (pt)
CA (1)	CA2527617A1 (pt)
DE (1)	DE602004028934D1 (pt)
DK (1)	DK1635839T3 (pt)
ES (2)	ES2352552T3 (pt)
IL (1)	IL172316A0 (pt)
MX (1)	MXPA05012745A (pt)
NO (1)	NO20060123L (pt)
PL (1)	PL1635839T3 (pt)
PT (1)	PT1635839E (pt)
RU (1)	RU2412190C2 (pt)
SA (1)	SA04250159B1 (pt)
SI (1)	SI1635839T1 (pt)
TW (1)	TWI349551B (pt)
WO (1)	WO2005032527A2 (pt)
ZA (1)	ZA200508296B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006063615A1 (en) *	2004-12-13	2006-06-22	Solvay Pharmaceuticals Gmbh	NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17β-HYDROXYSTEROID DEHYDROGENASE
US7524853B2 (en)	2003-06-10	2009-04-28	Solvay Pharmaceuticals B.V.	Compounds and their use in therapy
EP1742924A4 (en) *	2004-05-06	2010-10-06	Glaxosmithkline Llc	CALCILYTIC COMPOUNDS
JP2008517061A (ja) *	2004-10-20	2008-05-22	コンパスファーマシューティカルズリミティドライアビリティカンパニー	抗腫瘍剤としての化合物及びそれらの使用
FR2904000A1 (fr) *	2006-07-19	2008-01-25	Galderma Res & Dev S N C Snc	Modulateurs de hsd17b7 dans le traitement de l'acne ou de l'hyperseborrhee
FR2904318B1 (fr) *	2006-07-27	2011-02-25	Scras	Derives de pyrimidinone et leur utilisation comme medicament
US8080540B2 (en)	2006-09-19	2011-12-20	Abbott Products Gmbh	Therapeutically active triazoles and their use
US8288367B2 (en)	2006-11-30	2012-10-16	Solvay Pharmaceuticals Gmbh	Substituted estratriene derivatives as 17BETA HSD inhibitors
DE102007015169A1 (de) *	2007-03-27	2008-10-02	Universität des Saarlandes Campus Saarbrücken	17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
WO2009001214A2 (en) *	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
DE102007040243A1 (de)	2007-08-25	2009-02-26	Universität des Saarlandes	17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
CA2772760A1 (en) *	2008-12-23	2010-07-01	President And Fellows Of Harvard College	Small molecule inhibitors of necroptosis
WO2012025638A1 (en)	2010-08-27	2012-03-01	Universität des Saarlandes	Selective 17beta-hydroxysteroid dehydrogenase type 1 inhibitors
WO2012119605A1 (en) *	2011-03-10	2012-09-13	Akar Yahya Ahmed Abdellhafeez Salem	New disperse dye with potent anticancer activity
TW201520219A (zh) *	2013-03-12	2015-06-01	Lilly Co Eli	咪唑並吡啶化合物
US20160024098A1 (en)	2013-03-15	2016-01-28	President And Fellows Of Harvard College	Hybrid necroptosis inhibitors
BR112015031846A8 (pt)	2013-06-25	2018-03-06	Forendo Pharma Ltd	derivados de estratrientiazol, seus usos, e composição farmacêutica
JP6456373B2 (ja)	2013-06-25	2019-01-23	フォレンドファーマリミテッド	１７β−ヒドロキシステロイドデヒドロゲナーゼタイプ１の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体
WO2014207309A1 (en)	2013-06-25	2014-12-31	Forendo Pharma Ltd	Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
EP3089969A2 (en)	2014-01-03	2016-11-09	Elexopharm GmbH	Inhibitors of 17beta-hydroxysteroid dehydrogenases type 1 and type 2
WO2015114663A1 (en)	2014-01-30	2015-08-06	Council Of Scientific & Industrial Research	Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
GB201419102D0 (en) *	2014-10-27	2014-12-10	Imp Innovations Ltd	Novel compounds
CN107207562B (zh)	2014-12-23	2020-03-06	佛恩多制药有限公司	17β-HSD1抑制剂的前药
EP3237431B1 (en)	2014-12-23	2019-03-20	Forendo Pharma Ltd	Prodrugs of 17.beta.-hsd1 -inhibitors
WO2017075694A1 (en) *	2015-11-04	2017-05-11	Simon Fraser University	Antibiotic compounds, pharmaceutical formulations thereof and methods and uses therefor
MX391234B (es)	2017-06-08	2025-03-21	Forendo Pharma Ltd	Compuestos de estra-1,3,5(10)-trien-17-ona sustituida con 15.beta.-[3-propanamido] y sus 17-oximas para usarse en la inhibicion de 17.beta.-hidroxiesteroides deshidrogenasas.
CN109503572B (zh) *	2017-09-15	2021-10-08	上海交通大学	一种合成吲哚喹啉类化合物的方法
JP7417608B2 (ja)	2018-12-05	2024-01-18	フォレンドファーマリミテッド	１７－ｈｓｄ１阻害剤としての１６（１７）位でピラゾール環と縮合しているエストラ－１，３，５（１０）－トリエン化合物
JP2025516002A (ja) *	2022-04-28	2025-05-23	エナンタファーマシューティカルズインコーポレイテッド	ピリミジノン含有１７－ベータ－ヒドロキシステロイドデヒドロゲナーゼ１３型阻害剤
US20250154163A1 (en) *	2023-10-26	2025-05-15	Enanta Pharmaceuticals, Inc.	Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4742271B1 (pt) *	1968-06-20	1972-10-25
US3775027A (en)	1971-10-01	1973-11-27	Gray Manuf Co Inc	Two-speed pump
JPS62132884A (ja)	1985-12-05	1987-06-16	Mitsubishi Chem Ind Ltd	２−ベンジルチエノ〔２，３−ｄ〕ピリミジン−４（３Ｈ）−オン誘導体
EP0364598A4 (en)	1988-03-02	1992-01-15	Yoshitomi Pharmaceutical Industries, Ltd.	3,4-dihydrothieno 2,3-d¨pyrimidine compounds and pharmaceutical application thereof
US5597823A (en) *	1995-01-27	1997-01-28	Abbott Laboratories	Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists
JP3783810B2 (ja)	1997-01-14	2006-06-07	第一製薬株式会社	新規ベンゾフラノン誘導体及びその製造方法
JPH10273467A (ja)	1997-01-29	1998-10-13	Snow Brand Milk Prod Co Ltd	新規テトラロン又はベンゾピラノン誘導体及びその製造方法
AU9001698A (en)	1997-09-11	1999-03-29	Snow Brand Milk Products Co., Ltd.	Remedies for hormone-dependent diseases
TR200002784T2 (tr) *	1998-03-11	2000-12-21	Endorecherche, Inc	Tip 5 ve tip 3 17beta-Hidroksisteroid dehidrojenaz inhibitörleri ve bunların kullanımı için metodlar
EP1102753B1 (en)	1998-08-07	2007-02-28	Novartis Vaccines and Diagnostics, Inc.	Pyrazoles as estrogen receptor modulators
GB9929302D0 (en)	1999-12-11	2000-02-02	Univ Cardiff	Benzyl tetralins compositions and uses thereof
WO2002026706A2 (en)	2000-09-29	2002-04-04	Bayer Pharmaceuticals Corporation	17-beta-hydroxysteroid dehydrogenase-ii inhibitors
WO2003017974A1 (en)	2001-08-31	2003-03-06	Pantarhei Bioscience B.V.	Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method
TWI329108B (en)	2001-09-06	2010-08-21	Schering Corp	17-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
US6750248B2 (en)	2001-11-09	2004-06-15	National University Of Singapore	Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof

2004
- 2004-06-07 US US10/861,907 patent/US7465739B2/en not_active Expired - Fee Related
- 2004-06-08 TW TW093116411A patent/TWI349551B/zh not_active IP Right Cessation
- 2004-06-08 AR ARP040101983A patent/AR044650A1/es not_active Application Discontinuation
- 2004-06-09 KR KR1020057022958A patent/KR20060054189A/ko not_active Abandoned
- 2004-06-09 PL PL04803089T patent/PL1635839T3/pl unknown
- 2004-06-09 WO PCT/EP2004/006230 patent/WO2005032527A2/en not_active Ceased
- 2004-06-09 PT PT04803089T patent/PT1635839E/pt unknown
- 2004-06-09 AT AT04803089T patent/ATE479437T1/de active
- 2004-06-09 AU AU2004277311A patent/AU2004277311B8/en not_active Ceased
- 2004-06-09 BR BRPI0411295-4A patent/BRPI0411295A/pt not_active IP Right Cessation
- 2004-06-09 ES ES04803089T patent/ES2352552T3/es not_active Expired - Lifetime
- 2004-06-09 CA CA002527617A patent/CA2527617A1/en not_active Abandoned
- 2004-06-09 DE DE602004028934T patent/DE602004028934D1/de not_active Expired - Lifetime
- 2004-06-09 ZA ZA200508296A patent/ZA200508296B/xx unknown
- 2004-06-09 EP EP04803089A patent/EP1635839B1/en not_active Expired - Lifetime
- 2004-06-09 MX MXPA05012745A patent/MXPA05012745A/es active IP Right Grant
- 2004-06-09 DK DK04803089.4T patent/DK1635839T3/da active
- 2004-06-09 SI SI200431535T patent/SI1635839T1/sl unknown
- 2004-06-09 JP JP2006515869A patent/JP4605800B2/ja not_active Expired - Fee Related
- 2004-06-09 RU RU2006100033/04A patent/RU2412190C2/ru not_active IP Right Cessation
- 2004-06-09 CN CNA200480013515XA patent/CN1791412A/zh active Pending
- 2004-06-12 SA SA4250159A patent/SA04250159B1/ar unknown
- 2004-11-03 ES ES04805369T patent/ES2352554T3/es not_active Expired - Lifetime
2005
- 2005-12-01 IL IL172316A patent/IL172316A0/en unknown
2006
- 2006-01-09 NO NO20060123A patent/NO20060123L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
IL172316A0 (en)	2011-08-01
AU2004277311A1 (en)	2005-04-14
ES2352554T3 (es)	2011-02-21
JP2006527226A (ja)	2006-11-30
RU2412190C2 (ru)	2011-02-20
RU2006100033A (ru)	2007-07-20
BRPI0411295A (pt)	2006-08-01
TW200509937A (en)	2005-03-16
WO2005032527A3 (en)	2005-08-04
PL1635839T3 (pl)	2011-02-28
MXPA05012745A (es)	2006-05-17
ES2352552T3 (es)	2011-02-21
EP1635839B1 (en)	2010-09-01
CA2527617A1 (en)	2005-04-14
ATE479437T1 (de)	2010-09-15
WO2005032527B1 (en)	2005-09-22
CN1791412A (zh)	2006-06-21
SI1635839T1 (sl)	2010-12-31
DK1635839T3 (da)	2011-01-03
WO2005032527A2 (en)	2005-04-14
AU2004277311B2 (en)	2010-04-29
JP4605800B2 (ja)	2011-01-05
AR044650A1 (es)	2005-09-21
TWI349551B (en)	2011-10-01
US20050038053A1 (en)	2005-02-17
AU2004277311B8 (en)	2010-05-27
US7465739B2 (en)	2008-12-16
DE602004028934D1 (de)	2010-10-14
PT1635839E (pt)	2010-10-12
KR20060054189A (ko)	2006-05-22
ZA200508296B (en)	2007-01-31
EP1635839A2 (en)	2006-03-22
SA04250159B1 (ar)	2008-06-21

Legal Events

Date	Code	Title	Description
2013-02-11	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20060123L (no)	2006-03-09	Benzo(4,5)tieno(2,3-D)pyrimidin-4-oner og deres anvendelse i terapi
Miller et al.	2001	Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens
Messinger et al.	2006	New inhibitors of 17β-hydroxysteroid dehydrogenase type 1
ATE129013T1 (de)	1995-10-15	Steroid 5-alpha-reduktase.
PA8569501A1 (es)	2003-12-10	Compuestos utiles en terapia
MY132106A (en)	2007-09-28	New pyridazin-3(2h)-one derivatives
CA2645343A1 (en)	2007-09-20	Pyrrolopyrimidine derivatives used as hsp90 inhibitors
TW200516079A (en)	2005-05-16	Isethionate salt of a selective CDK4 inhibitor
DE60309667D1 (de)	2006-12-28	Biphenylderivate und ihre verwendung als antiandrogene
ATE432263T1 (de)	2009-06-15	Imidazol-4-ylmethanol-derivate zur verwendung als steroid c17-20 lyase-hemmer
CN101568547A (zh)	2009-10-28	作为17βHSD抑制剂的被取代的雌三烯衍生物
DE60307856D1 (de)	2006-10-05	Antitumorverbindung und ihre therapeutischen verwendungen
MXPA05008780A (es)	2005-10-18	Heterociclos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y preocedimientos para su preparacion.
AU2002214576A1 (en)	2002-04-22	Genes related to development of refractory prostate cancer
Jo et al.	2013	Chromenylchalcones with inhibitory effects on monoamine oxidase B
TW201043633A (en)	2010-12-16	Chemical compounds 751
Lee et al.	2014	Light-induced differences in conformational dynamics of the circadian clock regulator VIVID
K Morrow et al.	2011	Recent development of anticancer therapeutics targeting Akt
Mastracchio et al.	2019	Investigation of biaryl heterocycles as inhibitors of Wee1 kinase
CY1110589T1 (el)	2015-04-29	ΠΑΡΑΓΩΓΑ ΤΗΣ ΘΕΙΕΝΟ(2,3-b)ΠΥΡΙΔΙΝΗΣ ΧΡΗΣΙΜΑ ΩΣ ΑΝΤΑΓΩΝΙΣΤΕΣ ΤΗΣ ΟΡΜΟΝΗΣ ΑΠΕΛΕΥΘΕΡΩΣΕΩΣ ΓΟΝΑΔΟΤΡΟΠΟΥ ΟΡΜΟΝΗΣ
Indu et al.	2014	Molecular docking studies on flavonoid compounds: an insight into aromatase inhibitors
Couty et al.	2009	Ring expansion of 2-chloromethyl pyrrolidine or azetidine: Compared theoretical investigation
AU2003216084A1 (en)	2003-09-02	Methods for therapeutic treatment of benign prostatic hypertrophy (bph)
JP4686549B2 (ja)	2011-05-25	１７β−ヒドロキシステロイド・デヒドロゲナーゼの阻害剤としての新規な置換チオフェンピリミジノン誘導体
Michiels et al.	2009	Ligand-based NMR spectra demonstrate an additional phytoestrogen binding site for 17β-hydroxysteroid dehydrogenase type 1